Abstract | OBJECTIVES: BACKGROUND: METHODS: We undertook a randomized, double-blind, placebo-controlled study in 26 patients with FCHL, treated with pioglitazone or matching placebo 30 mg daily for 4 weeks, followed by 45 mg daily for 12 weeks. Positron emission tomography was used to measure MBF at rest and during adenosine-induced hyperemia and MGU during euglycemic hyperinsulinemic clamp at baseline and after treatment. RESULTS: Whereas no change was observed in the placebo group after treatment, patients receiving pioglitazone showed a significant increase in whole body glucose disposal (3.93 +/- 1.59 mg/kg/min to 5.24 +/- 1.65 mg/kg/min; p = 0.004) and MGU (0.62 +/- 0.26 micromol/g/min to 0.81 +/- 0.14 micromol/g/min; p = 0.0007), accompanied by a significant improvement in resting MBF (1.11 +/- 0.20 ml/min/g to 1.25 +/- 0.21 ml/min/g; p = 0.008). Furthermore, in the pioglitazone group HDL cholesterol (+28%; p = 0.003) and adiponectin (+156.2%; p = 0.0001) were increased and plasma insulin (-35%; p = 0.017) was reduced. CONCLUSIONS: In patients with FCHL treated with conventional lipid-lowering therapy, the addition of pioglitazone led to significant improvements in MGU and MBF, with a favorable effect on blood lipid and metabolic parameters. (A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemia; http://www.controlled-trials.com/mrct/trial/230761/ISRCTN78563659; ISRCTN78563659).
|
Authors | Rossi P Naoumova, Heiko Kindler, Lucia Leccisotti, Marco Mongillo, Muhammad T Khan, Clare Neuwirth, Mary Seed, Paul Holvoet, John Betteridge, Paolo G Camici |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 50
Issue 21
Pg. 2051-8
(Nov 20 2007)
ISSN: 1558-3597 [Electronic] United States |
PMID | 18021872
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Hypolipidemic Agents
- Thiazolidinediones
- Glucose
- Pioglitazone
|
Topics |
- Blood Glucose
(analysis)
- Coronary Circulation
(drug effects)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Glucose
(analysis, metabolism)
- Heart
(drug effects)
- Humans
- Hyperlipidemia, Familial Combined
(drug therapy)
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Hypolipidemic Agents
(therapeutic use)
- Male
- Middle Aged
- Pioglitazone
- Positron-Emission Tomography
- Thiazolidinediones
(pharmacology, therapeutic use)
- Treatment Outcome
|